Cargando…

A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial

BACKGROUND: Living with a chronic illness such as rheumatoid arthritis (RA) requires medications and therapies, as well as long-term follow-up with multidisciplinary clinical teams. Patient involvement in the shared decision-making process on medication regimens is an important element in promoting...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Siriwan, Athilingam, Ponrathi, Lahiri, Manjari, Cheung, Peter Pak Moon, He, Hong-Gu, Lopez, Violeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660247/
https://www.ncbi.nlm.nih.gov/pubmed/37930758
http://dx.doi.org/10.2196/48079
_version_ 1785137717740306432
author Lim, Siriwan
Athilingam, Ponrathi
Lahiri, Manjari
Cheung, Peter Pak Moon
He, Hong-Gu
Lopez, Violeta
author_facet Lim, Siriwan
Athilingam, Ponrathi
Lahiri, Manjari
Cheung, Peter Pak Moon
He, Hong-Gu
Lopez, Violeta
author_sort Lim, Siriwan
collection PubMed
description BACKGROUND: Living with a chronic illness such as rheumatoid arthritis (RA) requires medications and therapies, as well as long-term follow-up with multidisciplinary clinical teams. Patient involvement in the shared decision-making process on medication regimens is an important element in promoting medication adherence. Literature review and needs assessment showed the viability of technology-based interventions to equip patients with knowledge about chronic illness and competencies to improve their adherence to medications. Thus, a web-based intervention was developed to empower patients living with RA to adhere to their disease-modifying antirheumatic drugs (DMARDs) medication regimen. OBJECTIVE: This study aims to discuss the intervention mapping process in the design of a web-based intervention that supports patient empowerment to medication adherence and to evaluate its feasibility among patients living with RA. METHODS: The theory-based Patient Empowerment to Medication Adherence Programme (PE2MAP) for patients with RA was built upon the Zimmerman Psychological Empowerment framework, a web-based program launched through the Udemy website. PE2MAP was developed using a 6-step intervention mapping process: (1) needs assessment, (2) program objectives, (3) conceptual framework to guide the intervention, (4) program plan, (5) adoption, and (6) evaluation involving multidisciplinary health care professionals (HCPs) and a multimedia team. PE2MAP is designed as a 4-week web-based intervention program with a complementary RA handbook. A feasibility randomized controlled trial was completed on 30 participants from the intervention group who are actively taking DMARD medication for RA to test the acceptability and feasibility of the PE2MAP. RESULTS: The mean age and disease duration of the 30 participants were 52.63 and 8.50 years, respectively. The feasibility data showed 87% (n=26) completed the 4-week web-based PE2MAP intervention, 57% (n=17) completed all 100% of the contents, and 27% (n=8) completed 96% to 74% of the contents, indicating the overall feasibility of the intervention. As a whole, 96% (n=24) of the participants found the information on managing the side effects of medications, keeping fit, managing flare-ups, and monitoring joint swelling/pain/stiffness as the most useful contents of the intervention. In addition, 88% (n=23) and 92% (n=24) agreed that the intervention improved their adherence to medications and management of their side effects, including confidence in communicating with their health care team, respectively. The dos and do nots of traditional Chinese medicine were found by 96% (n=25) to be useful. Goal setting was rated as the least useful skill by 6 (23.1%) of the participants. CONCLUSIONS: The web-based PE2MAP intervention was found to be acceptable, feasible, and effective as a web-based tool to empower patients with RA to manage and adhere to their DMARD medications. Further well-designed randomized controlled trials are warranted to explore the effectiveness of this intervention in the management of patients with RA.
format Online
Article
Text
id pubmed-10660247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-106602472023-11-06 A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial Lim, Siriwan Athilingam, Ponrathi Lahiri, Manjari Cheung, Peter Pak Moon He, Hong-Gu Lopez, Violeta JMIR Form Res Original Paper BACKGROUND: Living with a chronic illness such as rheumatoid arthritis (RA) requires medications and therapies, as well as long-term follow-up with multidisciplinary clinical teams. Patient involvement in the shared decision-making process on medication regimens is an important element in promoting medication adherence. Literature review and needs assessment showed the viability of technology-based interventions to equip patients with knowledge about chronic illness and competencies to improve their adherence to medications. Thus, a web-based intervention was developed to empower patients living with RA to adhere to their disease-modifying antirheumatic drugs (DMARDs) medication regimen. OBJECTIVE: This study aims to discuss the intervention mapping process in the design of a web-based intervention that supports patient empowerment to medication adherence and to evaluate its feasibility among patients living with RA. METHODS: The theory-based Patient Empowerment to Medication Adherence Programme (PE2MAP) for patients with RA was built upon the Zimmerman Psychological Empowerment framework, a web-based program launched through the Udemy website. PE2MAP was developed using a 6-step intervention mapping process: (1) needs assessment, (2) program objectives, (3) conceptual framework to guide the intervention, (4) program plan, (5) adoption, and (6) evaluation involving multidisciplinary health care professionals (HCPs) and a multimedia team. PE2MAP is designed as a 4-week web-based intervention program with a complementary RA handbook. A feasibility randomized controlled trial was completed on 30 participants from the intervention group who are actively taking DMARD medication for RA to test the acceptability and feasibility of the PE2MAP. RESULTS: The mean age and disease duration of the 30 participants were 52.63 and 8.50 years, respectively. The feasibility data showed 87% (n=26) completed the 4-week web-based PE2MAP intervention, 57% (n=17) completed all 100% of the contents, and 27% (n=8) completed 96% to 74% of the contents, indicating the overall feasibility of the intervention. As a whole, 96% (n=24) of the participants found the information on managing the side effects of medications, keeping fit, managing flare-ups, and monitoring joint swelling/pain/stiffness as the most useful contents of the intervention. In addition, 88% (n=23) and 92% (n=24) agreed that the intervention improved their adherence to medications and management of their side effects, including confidence in communicating with their health care team, respectively. The dos and do nots of traditional Chinese medicine were found by 96% (n=25) to be useful. Goal setting was rated as the least useful skill by 6 (23.1%) of the participants. CONCLUSIONS: The web-based PE2MAP intervention was found to be acceptable, feasible, and effective as a web-based tool to empower patients with RA to manage and adhere to their DMARD medications. Further well-designed randomized controlled trials are warranted to explore the effectiveness of this intervention in the management of patients with RA. JMIR Publications 2023-11-06 /pmc/articles/PMC10660247/ /pubmed/37930758 http://dx.doi.org/10.2196/48079 Text en ©Siriwan Lim, Ponrathi Athilingam, Manjari Lahiri, Peter Pak Moon Cheung, Hong-Gu He, Violeta Lopez. Originally published in JMIR Formative Research (https://formative.jmir.org), 06.11.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Lim, Siriwan
Athilingam, Ponrathi
Lahiri, Manjari
Cheung, Peter Pak Moon
He, Hong-Gu
Lopez, Violeta
A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title_full A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title_fullStr A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title_full_unstemmed A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title_short A Web-Based Patient Empowerment to Medication Adherence Program for Patients With Rheumatoid Arthritis: Feasibility Randomized Controlled Trial
title_sort web-based patient empowerment to medication adherence program for patients with rheumatoid arthritis: feasibility randomized controlled trial
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660247/
https://www.ncbi.nlm.nih.gov/pubmed/37930758
http://dx.doi.org/10.2196/48079
work_keys_str_mv AT limsiriwan awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT athilingamponrathi awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT lahirimanjari awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT cheungpeterpakmoon awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT hehonggu awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT lopezvioleta awebbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT limsiriwan webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT athilingamponrathi webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT lahirimanjari webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT cheungpeterpakmoon webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT hehonggu webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial
AT lopezvioleta webbasedpatientempowermenttomedicationadherenceprogramforpatientswithrheumatoidarthritisfeasibilityrandomizedcontrolledtrial